

# 2007 Annual Index

IMPROVING PATIENT CARE THROUGH ESOTERIC LABORATORY TESTING

JANUARY 2008

## FEATURE ARTICLES

- The Pharmacogenetics of Tamoxifen Therapy... 1/07
- A Practical Approach to Testing  
for von Willebrand Disease..... 2/07
- Macroprolactin—Big-Big Molecules  
Create Big Problems in Diagnosis  
of Hyperprolactinemia ..... 3/07
- Laboratory and Molecular Diagnosis  
of Primary Hyperoxaluria and Oxalosis ..... 4/07
- Growth Hormone Deficiency—  
Biochemical Testing for Diagnosis  
and Treatment Monitoring ..... 5/07
- Glutamic Acid Decarboxylase Autoimmunity  
With Brainstem, Extrapyramidal, and Spinal  
Cord Dysfunction ..... 6/07
- Rapid PCR —The New Gold  
Standard for Dermal and Genital  
Testing for HSV and VZV ..... 7/07
- Laboratory Analysis for  
Monoclonal Gammopathies ..... 8/07
- A Clinical Conundrum: The Diagnosis  
and Treatment of Androgen Deficiency  
in Older Men ..... 9/07
- A Practical Approach to the Patient  
With Subclinical Hypothyroidism ..... 9/07
- Influenza and the Role  
of Laboratory Testing..... 10/07
- Vancomycin-Resistant Enterococci:  
Colonization, Infection, Detection,  
and Treatment ..... 11/07
- Newly Diagnosed Multiple Myeloma:  
Cytogenetic Classification and  
Evidence-Based Therapy Guidelines ..... 12/07

## NEW TEST ANNOUNCEMENTS

Age-Related Macular Degeneration, Risk Analysis, Y402H & A69S, Blood . . . . .	8/07	C5-OH Acylcarnitine, Quantitative, Urine . . . . .	10/07
Allo-isoleucine, Blood Spot . . . . .	11/07	Celiac-Associated HLA-DQ Alpha 1 and DQ Beta 1 High-Resolution DNA Typing, Blood . . . . .	11/07
Alpha-Fetoprotein (AFP) L3% and Total, Hepatocellular Carcinoma Tumor Marker, Serum . . . . .	5/07	CFTR Gene, Full Gene Analysis . . . . .	8/07
Alveolar Rhabdomyosarcoma (ARMS) 13q14 ( <i>FKHR</i> ) Rearrangement, FISH, Tissue . . . . .	11/07	CFTR Gene, Known Mutation . . . . .	8/07
Aminolevulinic Acid Dehydratase (ALA-D), Erythrocytes . . . . .	11/07	Chromosome Analysis, Replication Banding . . . . .	10/07
Antimicrobial Susceptibility, <i>Mycobacterium tuberculosis</i> Complex, Method of Proportion . . . . .	6/07	<i>Clostridium difficile</i> Toxin Gene Detection by Rapid PCR . . . . .	8/07
Antimicrobial Susceptibility, <i>Mycobacterium tuberculosis</i> Complex, Rapid Broth Method . . . . .	6/07	<i>Coccidioides</i> DNA Detection, Rapid PCR . . . . .	5/07
Autosomal Recessive Polycystic Kidney Disease (ARPKD), Full Gene Analysis . . . . .	9/07	Complement, Alternate Pathway (AH50), Functional, Serum . . . . .	7/07
Autosomal Recessive Polycystic Kidney Disease (ARPKD), Known Mutation . . . . .	9/07	Cortisol/Cortisone, Free, Random Urine . . . . .	4/07
B-Cell Lymphoma, FISH, Blood and Bone Marrow . . . . .	6/07	Culture, Virus, Non-Respiratory . . . . .	9/07
B-Cell Phenotyping Profile for Immunodeficiency and Immune Competence Assessment, Blood . . . . .	4/07	Culture, Virus, Respiratory . . . . .	9/07
Beta-2 Glycoprotein 1 Antibodies, IgG, IgM, and IgA, Serum . . . . .	4/07	Cytomegalovirus (CMV) CD8 T-Cell Immune Competence, Quantitative Assessment by Flow Cytometry . . . . .	8/07
Biotinidase Deficiency, <i>BTD</i> Full Gene Analysis . . . . .	11/07	Drug Screen, Prescription/OTC, Urine . . . . .	2/07
Biotinidase Deficiency, <i>BTD</i> Gene, Known Mutation . . . . .	11/07	Fabry Disease, Full Gene Analysis . . . . .	9/07
BK Virus DNA by PCR, Plasma or Urine . . . . .	10/07	Fabry Disease, Known Mutation . . . . .	9/07
Bullous Pemphigoid, BP180 & BP230, IgG Antibodies, Serum . . . . .	6/07	Familial Adenomatous Polyposis (FAP) Large Deletion/Duplication . . . . .	9/07
C4 Acylcarnitine, Quantitative, Urine . . . . .	10/07	Fetomaternal Bleed, Flow Cytometry, Blood . . . . .	4/07
C5-DC Acylcarnitine, Quantitative, Urine . . . . .	10/07	Gliadin (Deamidated) Antibodies Evaluation, IgG and IgA, Serum . . . . .	12/07
		Gliadin (Deamidated) Antibody, IgA, Serum . . . . .	12/07
		Gliadin (Deamidated) Antibody, IgG, Serum . . . . .	12/07

Herpes Simplex Virus (HSV) Antibody Screen, IgM, by EIA, Serum . . . . .	9/07	T-Cell Receptor Excision Circles (TREC) Analysis for Immune Reconstitution. . . . .	2/07
HIV-1 Genotypic Drug Resistance Mutation Analysis, with Reflex to Phenotypic Drug Resistance Prediction, Plasma. . . . .	11/07	ZAP-70, Chronic Lymphocytic Leukemia (CLL) Prognosis . . . . .	4/07
HIV-1 Phenotypic Drug Resistance Prediction (Add-On). . . . .	11/07	Tamoxifen and Metabolites, Serum . . . . .	8/07
Immunoglobulin Total Light Chains, Urine . . . .	4/07	1p36.3 Microdeletion Syndrome, FISH . . . . .	10/07
JC Virus DNA by PCR, Spinal Fluid . . . . .	10/07	Warfarin Sensitivity, Genotype. . . . .	7/07
<b>UPDATES</b>			
KIT Asp816Val Mutation Analysis, Qualitative PCR . . . . .	2/07	Changes to Drug Screening and Prescription and Over-The-Counter Drug Testing . . . . .	1/07
Leukemia Lymphoma Immunophenotyping by Flow Cytometry, Tissue . . . . .	7/07	Human Herpesvirus-6 Testing by Rapid PCR . .	1/07
Macroprolactin, Serum . . . . .	3/07	Light-Protected Samples . . . . .	4/07
Monoclonal Protein Study, Expanded Panel, Serum . . . . .	2/07	2006 Reader Survey Results . . . . .	5/07
Myxoid/Round Cell Liposarcoma 12q13 ( <i>CHOP</i> ) Rearrangement, FISH, Paraffin-Embedded Tissue . . . . .	10/07	Bacterial Antigen Testing–Specimen Type Change . . . . .	8/07
Niemann-Pick Type C Disease, Known Mutation. . . . .	11/07	New Requirement for Submissions for Surgical Pathology Consultations . . . . .	9/07
Niemann-Pick Type C, Full Gene Analysis . . . .	11/07	Algorithms and New Tests for the Laboratory Diagnosis of Acute and Cutaneous Porphyrias . . . . .	11/07
Niemann-Pick Type C, Large Deletion/ Duplication, Molecular Analysis . . . . .	11/07	Macroprolactin Reporting Change . . . . .	11/07
Pain Clinic Survey 10, Urine. . . . .	2/07	CAP and ASCO HER2 Guidelines for 2008 . . . .	12/07
<b>ABSTRACTS OF INTEREST</b>			
Porphobilinogen (PBG) Deaminase, Erythrocytes. . . . .	11/07	Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion . . . . .	3/07
Streptococcal Antibodies Profile . . . . .	2/07	Copper Deficiency Myelopathy (Human Swayback) . . . . .	4/07
T-Cell Acute Lymphoblastic Leukemia (T-ALL), FISH . . . . .	12/07	The Role of Mammography in Male Patients With Breast Symptoms . . . . .	6/07
T-Cell Lymphoma, FISH, Blood or Bone Marrow . . . . .	12/07	Use of Cellular Telephones in the Hospital Environment . . . . .	8/07
T-Cell Lymphoma, FISH, Tissue . . . . .	12/07		

Stratification of Patient Risk Based on  
Prostate-Specific Antigen Doubling Time  
After Radical Retropubic Prostatectomy . . . . . 9/07

Using Smudge Cells on Routine Blood  
Smears to Predict Clinical Outcome in  
Chronic Lymphocytic Leukemia:  
A Universally Available Prognostic Test . . . . . 10/07

Cytochrome P450 2D6 Genotype Variation  
and Venlafaxine Dosage . . . . . 11/07

Long-term Results of Response to Therapy,  
Time to Progression, and Survival With  
Lenalidomide Plus Dexamethasone  
in Newly Diagnosed Myeloma. . . . . 12/07

**FOR YOUR INFORMATION**

Accreditation and Licensing  
Inspection Checklist . . . . . 1/07

National Medical Laboratory  
Professionals Week . . . . . 4/07



3050 Superior Drive NW  
Rochester, Minnesota 55901  
[www.MayoMedicalLaboratories.com](http://www.MayoMedicalLaboratories.com)  
800-533-1710

©2008  
MC2831-0108

**Editorial Board**

Jane Dale, MD  
Denise Masoner  
Debra Novak  
Bradley Ross

**Communiqué Staff**

Medical Editor: Jane Dale, MD  
Managing Editor: Denise Masoner  
Art Director: Ann Rebidas

The *Communiqué* is published by Mayo Reference Services to provide laboratorians with information on new diagnostic tests, changes in procedures or normal values, and continuing medical education programs and workshops.

A complimentary subscription of the *Communiqué* is provided to Mayo Medical Laboratories' clients. Please send address changes to [communiqué@mayo.edu](mailto:communiqué@mayo.edu) or *Communiqué*, Superior Drive Support Center, 3050 Superior Drive NW, Rochester, MN 55901, or call us at 800-533-1710.